Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARγ agonists

Journal of Medicinal Chemistry

Volumn 49, Issue 14, 2006, Pages 4072-4084

  Chittiboyina, Amar G ^a   Venkatraman, Meenakshi S ^a   Mizuno, Cassia S ^a   Desai, Prashant V ^a   Patny, Akshay ^a   Benson, Stephen C ^b   Ho, Christopher I ^b   Kurtz, Theodore W ^c,f   Pershadsingh, Harrihar A ^d,e,f   Avery, Mitchell A ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b CALIFORNIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Bethesda Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2' [[8 [[2 [4 [(2,4 DIOXO 1,3 THIAZOLIDIN 5 YL)METHYL]PHENOXY]ETHYL](METHYL)AMINO] 8 OXOOCTANE 1,3 DIYL]BIS(THIO)]BIS(2 OXOETHANAMINIUM)DICHLORIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIOXIDANT; CIGLITAZONE; DITHIOLANE THIAZOLIDINEDIONE; GLITAZONE DERIVATIVE; N [2 [4 [(2,4 DIOXO 1,3 THIAZOLIDIN 5 YL)METHYL]PHENOXY]ETHYL] 5 (1,2 DITHIOLAN 3 YL) N METHYLPENTANAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENYLACETIC ACID DERIVATIVE; PIOGLITAZONE; ROSIGLITAZONE; THIOCTIC ACID; TROGLITAZONE; UNCLASSIFIED DRUG;

ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INSULIN SENSITIVITY; KERATINOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; RESTENOSIS; SKIN INFLAMMATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOCYTES; ADIPOGENESIS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTILIPEMIC AGENTS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; INSULIN RESISTANCE; INTERLEUKINS; KERATINOCYTES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHENYLACETATES; PPAR GAMMA; RATS; RATS, ZUCKER; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINEDIONES; THIOCTIC ACID;

EID: 33745850802     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0510880     Document Type: Article

References (54)

1. Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R. The PPARs: From orphan receptors to drug discovery. J. Med. Chem. 2000, 43, 527-550.
2. Caldwell, S. H.; Hespenheide, E. E.; Redick, J. A.; Iezzoni, J. C.; Battle, E. H.; Sheppard, B. L. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2001, 96, 519-525.
3. Das, S. K.; Reddy, K. A.; Abbineni, C.; Iqbal, J.; Suresh, J.; Premkumar, M.; Chakrabarti, R. Novel thieno oxazine analogues as antihyperglycemic and lipid modulating agents. Bioorg. Med. Chem. Lett. 2003, 13, 399-403.
4. Devasthale, P. V.; Chen, S.; Jeon, Y.; Qu, F.; Shao, C.; Wang, W.; Zhang, H.; Farrelly, D.; Golla, R.; Grover, G.; Harrity, T.; Ma, Z.; Moore, L.; Ren, J.; Seethala, R.; Cheng, L.; Sleph, P.; Sun, W.; Tieman, A.; Wetterau, J. R.; Doweyko, A.; Chandrasena, G.; Chang, S. Y.; Humphreys, W. G.; Sasseville, V. G.; Biller, S. A.; Ryono, D. E.; Selan, F.; Hariharan, N.; Cheng, P. T. W. Design and Synthesis of N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl- oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities. J. Med. Chem. 2005, 48, 2248-2250.
5. Henke, B. R. Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists for the Treatment of Type 2 Diabetes. J. Med. Chem. 2004, 47, 4118-4127.
6. Koyama, H.; Miller, D. J.; Boueres, J. K.; Desai, R. C.; Jones, A. B.; Berger, J. P.; MacNaul, K. L.; Kelly, L. J.; Doebber, T. W.; Wu, M. S.; Zhou, G.; Wang, P.-R.; Ippolito, M. C.; Chao, Y.-S.; Agrawal, A. K.; Franklin, R.; Heck, J. V.; Wright, S. D.; Moller, D. E.; Sahoo, S. P. (2R)-2-Ethylchromane-2- carboxylic Acids: Discovery of Novel PPARα/γ Dual Agonists as Antihyperglycemic and Hypolipidemic Agents. J. Med. Chem. 2004, 47, 3255-3263.
7. Rybczynski, P. J.; Zeck, R. E.; Dudash, J., Jr.; Combs, D. W.; Burris, T. P.; Yang, M.; Osborne, M. C.; Chen, X.; Demarest, K. T. Benzoxazinones as PPARγ Agonists. 2. SAR of the Amide Substituent and In Vivo Results in a Type 2 Diabetes Model. J. Med. Chem. 2004, 47, 196-209.
8. Xu, Y.; Rito, C. J.; Etgen, G. J.; Ardecky, R. J.; Bean, J. S.; Bensch, W. R.; Bosley, J. R.; Broderick, C. L.; Brooks, D. A.; Dominianni, S. J.; Hahn, P. J.; Liu, S.; Mais, D. E.; Montrose-Rafizadeh, C.; Ogilvie, K. M.; Oldham, B. A.; Peters, M.; Rungta, D. K.; Shuker, A. J.; Stephenson, G. A.; Tripp, A. E.; Wilson, S. B.; Winneroski, L. L.; Zink, R.; Kauffman, R. F.; McCarthy, J. R. Design and Synthesis of α-Aryloxy-α-methylhydrocinnamic Acids: A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/γ Agonists. J. Med. Chem. 2004, 47, 2422-2425.
9. Vasudevan, A. R.; Balasubramanyam, A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol. Ther. 2004, 6, 850-863.
10. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285, 2486-2497.
11. Jacob, S.; Streeper, R. S.; Fogt, D. L.; Hokama, J. Y.; Tritschler, H. J.; Dietze, G. J.; Henriksen, E. J. The antioxidant α-lipoic acid enhances insulin-stimulated glucose metabolism in insulin-resistant rat skeletal muscle. Diabetes 1996, 45, 1024-1029.
12. Vasdev, S.; Gill, V.; Longerich, L. Antihypertensive effect of α-lipoic acid supplementation. Curr. Topics Nutraceut. Res. 2004, 2, 137-151.
13. Mervaala, E.; Finckenberg, P.; Lapatto, R.; Muller, D. N.; Park, J.-K.; Dechend, R.; Ganten, D.; Vapaatalo, H.; Luft, F. C. Lipoic acid supplementation prevents angiotensin II-induced renal injury. Kidney Int. 2003, 64, 501-508.
14. Mizuno, C. S.; Chittiboyna, A. G.; Venkatraman, M. S.; Avery, M. A.; Meingassner, J.; Ho, C.; Benson, S. C.; Varani, J.; Ellis, C. N.; Kurtz, T. W.; Pershadsingh, H. A. α-lipoic acid-based PPAR γ-agonists for treating type II diabetes. Abstracts of Papers; 229th ACS National Meeting, San Diego, CA, Mar 13-17, 2005; American Chemical Society: Washington, DC, 2005; MEDI-203.
15. Avery, M. A.; Patny, A.; Chittiboyina, A.; Desai, P. V.; Venkatraman, M. S.; Mizuno, C.; Ho, C.; Benson, S. C.; Kurtz, T. W.; Pershadsingh, H. A. α-Lipoic acid-based PPARγ agonists as anti-diabetic agents: Design, synthesis and docking studies. Abstracts of Papers; 227th ACS National Meeting, Anaheim, CA, Mar 28-Apr 1, 2004; American Chemical Society: Washington, DC, 2004; COMP-227.
16. Pershadsingh, H. A.; Avery, M. A. Dithiolane derivatives: PCT Int. Appl. 2001, 117 pp. WO 2001025226 CAN 134: 290422.
17. Pershadsingh, H. A.; Avery, M. A. Preparation of dithiolanyl thiazolidinediones as peroxisome proliferator-activated receptor-γ activators Application: U.S. 2002, 38 pp., Cont.-in-part of U.S. Ser. No. 6, 204,288. US 6353011 CAN 136: 216739.
18. Pershadsingh, H. A.; Ho, C. I.; Rajamani, J.; Lee, C.; Chittiboyina, A. G.; Deshpande, R.; Kurtz, T. W.; Chan, J. Y.; Avery, M. A.; Benson, S. C. α-lipoic acid is a weak dual PPARα/γ agonist: an ester derivative with increased PPARα/γ efficacy and antioxidant activity. J. Appl. Res. 2005, 5, 510-523. URL: http://jrnl/appliedresearch.com/articles/ Vol5Iss4/.
19. Tomkinson, N. C. O.; Sefler, A. M.; Plunket, K. D.; Blanchard, S. G.; Parks, D. J.; Willson, T. M. Solid-phase synthesis of hybrid thiazolidinedione-fatty acid PPARγ ligands. Bioorg. Med. Chem. Lett. 1997, 7, 2491-2496.
20. Fan, Y.-H.; Chen, H.; Natarajan, A.; Guo, Y.; Harbinski, F.; Iyasere, J.; Christ, W.; Aktas, H.; Halperin, J. A. Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium. Bioorg. Med. Chem. Lett. 2004, 14, 2547-2550.
21. Dominguez, C.; Csaky, A. G.; Plumet, J. Chemoselective reduction in carbonyl-conjugated vinylfurans by the magnesium-methanol system. Tetrahedron Lett. 1991, 32, 4183-4184.
22. Han, G.; Tamaki, M.; Hruby, V. J. Fast, efficient and selective deprotection of the tert-butoxycarbonyl (Boc) group using HCl/dioxane (4 M). J. Pept. Res. 2001, 58, 338-341.
23. Marlett, E. M.; Park, W. S. Dimethylethylamine alane and N-methylpyrrolidine alane. A convenient synthesis of alane, a useful selective reducing agent in organic synthesis. J. Org. Chem. 1990, 55, 2968-2969.
24. Field, L.; Lawson, J. E. Organic disulfides and related substances. I. Oxidation of thiols to disulfides with lead tetraacetate. J. Am. Chem. Soc. 1958, 80, 838-841.
25. Gunsalus, I. C.; Barton, L. S.; Gruber, W. Biosynthesis and structure of lipoic acid derivatives. J. Am. Chem. Soc. 1956, 78, 1763-1766.
26. Adams, A. D.; Berger, J. P.; Berger, G. D.; Fitch, K. J.; Graham, D. W.; Jones, A. B.; Von Langen, D.; et al. Preparation of [(heterocyclyloxy)alkoxy- and -alkylthio]phenylalkanoates and analogs as peroxisome proliferator-activated receptor antagonists Application: WO 97-US1749 9728137.
27. Goswami, A.; Goswami, B. N.; Borthakur, N.; Rastogi, R. C. A convenient synthesis of amines from phenols. J. Chem. Res., Synop. 1996, 424-425.
28. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-γ. Nature 1998, 395, 137-143.
29. Ostberg, T.; Svensson, S.; Selen, G.; Uppenberg, J.; Thor, M.; Sundbom, M.; Sydow-Backman, M.; Gustavsson, A. L.; Jendeberg, L. A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J. Biol. Chem. 2004, 279, 41124-41130.
30. Thor, M.; Beierlein, K.; Dykes, G.; Gustavsson, A. L.; Heidrich, J.; Jendeberg, L.; Lindqvist, B.; Pegurier, C.; Roussel, P.; Slater, M.; Svensson, S.; Sydow-Backman, M.; Thornstrom, U.; Uppenberg, J. Synthesis and pharmacological evaluation of a new class of peroxisome proliferator-activated receptor modulators. Bioorg. Med. Chem. Lett. 2002, 12, 3565-3567.
31. Venkatraman, M. S.; Chittiboyina, A.; Meingassner, J.; Ho, C. I.; Varani, J.; Ellis, C. N.; Avery, M. A.; Pershadsingh, H. A.; Kurtz, T. W.; Benson, S. C. α-Lipoic acid-based PPARgamma agonists for treating inflammatory skin diseases. Arch. Dermatol. Res. 2004, 296, 97-104.
32. Usui, S.; Suzuki, T.; Hattori, Y.; Etoh, K.; Fujieda, H.; Nishizuka, M.; Imagawa, M.; Nakagawa, H.; Kohda, K.; Miyata, N. Design, synthesis, and biological activity of novel PPARγ ligands based on rosiglitazone and 15d-PGJ2. Bioorg. Med. Chem. Lett. 2005, 15, 1547-1551.
33. Iwata, Y.; Miyamoto, S.; Takamura, M.; Yanagisawa, H.; Kasuya, A. Interaction between peroxisome proliferator-activated receptor γ and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione. J. Mol. Graphics Model. 2001, 19, 536-542.
34. Yanagisawa, H.; Takamura, M.; Yamada, E.; Fujita, S.; Fujiwara, T.; Yachi, M.; Isobe, A.; Hagisawa, Y. Novel oximes containing a 5-benzyl-2,4-thiazolidinedione moiety as antihyperglycemic agents: synthesis and structure-activity relationship. Bioorg. Med. Chem. Lett. 2000, 10, 373-375.
35. Sinkula, A. A.; Yalkowsky, S. H. Rationale for design of biologically reversible drug derivatives: prodrugs. J. Pharm. Sci. 1975, 64, 181-210.
36. Stwlla, V. J. Preface. Adv. Drug Delivery Rev. 1996, 19, 111-114.
37. Jiang, C.; Ting, A. T.; Seed, B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391, 82-86.
38. Ricote, M.; Li, A. C.; Willson, T. M.; Kelly, C. J.; Glass, C. K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998, 391, 79-82.
39. Yang, X. Y.; Wang, L. H.; Chen, T.; Hodge, D. R.; Resau, J. H.; DaSilva, L.; Farrar, W. L. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J. Biol. Chem. 2000, 275, 4541-4544.
40. Barak, Y.; Nelson, M. C.; Ong, E. S.; Jones, Y. Z.; Ruiz-Lozano, P.; Chien, K. R.; Koder, A.; Evans, R. M. PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell 1999, 4, 585-595.
41. Kubota, N.; Terauchi, Y.; Miki, H.; Tamemoto, H.; Yamauchi, T.; Komeda, K.; Satoh, S.; Nakano, R.; Ishii, C.; Sugiyama, T.; Eto, K.; Tsubamoto, Y.; Okuno, A.; Murakami, K.; Sekihara, H.; Hasegawa, G.; Naito, M.; Toyoshima, Y.; Tanaka, S.; Shiota, K.; Kitamura, T.; Fujita, T.; Ezaki, O.; Aizawa, S.; Nagai, R.; Tobe, K.; Kimura, S.; Kadowaki, T. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 1999, 4, 597-609.
42. Rosen, E. D.; Sarraf, P.; Troy, A. E.; Bradwin, G.; Moore, K.; Milstone, D. S.; Spiegelman, B. M.; Mortensen, R. M. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 1999, 4, 611-617.
43. Wu, Z.; Xie, Y.; Bucher, N. L. R.; Farmer, S. R. Conditional ectopic expression of C/EBPb in NIH-3T3 cells induces PPARγ and stimulates adipogenesis. Genes Dev. 1995, 9, 2350-2363.
44. Hu, E.; Tontonoz, P.; Spiegelman, B. M. Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPα. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 9856-9860.
45. Sawa, M.; Tsukamoto, T.; Kiyoi, T.; Kurokawa, K.; Nakajima, F.; Nakada, Y.; Yokota, K.; Inoue, Y.; Kondo, H.; Yoshino, K. New Strategy for Antidrug Application: Development of Metalloproteinase Inhibitors as Antipsoriatic Drugs. J. Med. Chem. 2002, 45, 930-936.
46. Bhagavathula, N.; Nerusu, K. C.; Lal, A.; Ellis, C. N.; Chittiboyina, A.; Avery, M. A.; Ho, C. I.; Benson, S. C.; Pershadsingh, H. A.; Kurtz, T. W.; Varani, J. Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J. Invest. Dermatol. 2004, 122, 130-139.
47. Theocharis, S.; Margeli, A.; Kouraklis, G. Peroxisome proliferator activated receptor-γ ligands as potent antineoplastic agents. Curr. Med. Chem.: Anti-Cancer Agents 2003, 3, 239-251.
48. Chintharlapalli, S.; Smith, R., 3rd; Samudio, I.; Zhang, W.; Safe, S. 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl)methanes induce peroxisome proliferator-activated receptor γ-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells. Cancer Res. 2004, 64, 5994-6001.
49. Reed, M. J.; Scribner, K. A. In-vivo and in-vitro models of type 2 diabetes in pharmaceutical drug discovery. Diabetes Obes. Metab. 1999, 1, 75-86.
50. Phillips, M. S.; Liu, Q.; Hammond, H. A.; Dugan, V.; Hey, P. J.; Caskey, C. J.; Hess, J. F. Leptin receptor missense mutation in the fatty Zucker rat. Nat. Genet. 1996, 13, 18-19.
51. Benson, S. C.; Pershadsingh, H. A.; Ho, C. I.; Chittiboyina, A.; Desai, P.; Pravenec, M.; Qi, N.; Wang, J.; Avery, M. A.; Kurtz, T. W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43, 993-1002.
52. Berger, J. P.; Petro, A. E.; Macnaul, K. L.; Kelly, L. J.; Zhang, B. B.; Richards, K.; Elbrecht, A.; Johnson, B. A.; Zhou, G.; Doebber, T. W.; Biswas, C.; Parikh, M.; Sharma, N.; Tanen, M. R.; Thompson, G. M.; Ventre, J.; Adams, A. D.; Mosley, R.; Surwit, R. S.; Moller, D. E. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol. Endocrinol. 2003, 17, 662-676.
53. Chaput, E.; Saladin, R.; Silvestre, M.; Edgar, A. D. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem. Biophys. Res. Commun. 2000, 271, 445-450.
54. Pershadsingh, H. A. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin. Investig. Drugs 2004, 13, 215-228.